Samsung BioLogics signed a contract with GI Innovation for immunochemotherapy services at its headquarters in Incheon, South Korea. GI Innovation signed this second contract with Samsung BioLogics based the high quality and production services for their first project with Samsung in June of last year. This agreement is part of a multi-project deal under which Samsung BioLogics will provide contract services from the development of cell lines to the production of Phase I drug substances for GI...